NCT02900664 2022-03-29A Study of PDR001 in Combination With CJM112, EGF816, IlarisĀ® (Canakinumab) or MekinistĀ® (Trametinib)NovartisPhase 1 Completed283 enrolled
NCT01138085 2017-11-13Safety, Pharmacokinetics (PK) of AKT and MEK CombinationGlaxoSmithKlinePhase 1 Completed240 enrolled